Michael Kaufman | Authors

ADT in Prostate Cancer Linked to Risk of Cardiac Death

October 30, 2014

A study found that prostate cancer patients with a history of heart problems are at increased risk of cardiac death following androgen-deprivation therapy.

Ibrutinib Yields Durable Responses in CLL

June 25, 2013

Monotherapy with the investigational oral Bruton's tyrosine kinase inhibitor ibrutinib was well tolerated and produced durable responses in a phase Ib/II, open-label, multicenter study of 85 patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Bisphosphonate Effective in Treating Osteonecrosis Pain in Pediatric ALL

June 24, 2013

Use of the bisphosphonate pamidronate (Aredia) may be “more efficient” than standard regimens as palliative treatment for symptoms of acute symptomatic osteonecrosis in pediatric patients with acute lymphoblastic leukemia.

ASCO: Vinegar Screening Significantly Reduces Cervical Cancer Mortality

June 07, 2013

Biennial visual inspection with acetic acid (vinegar) screening by trained public health workers significantly reduced cervical cancer mortality in a large cluster-randomized controlled trial conducted among thousands of women from poor neighborhoods in Mumbai, India.

ASCO: Updated Analyses Confirm Safety and Efficacy of Ra-223 in CRPC

June 06, 2013

Further analyses of data subsets from the ALSYMPCA study of the alpha particle-emitting isotope Ra-223 (Xofigo) were presented at ASCO, providing additional evidence of efficacy and safety of the recently FDA approved therapeutic agent.

ASCO: Adding Curcuminoids to Docetaxel Shows Promise in Castration-Resistant Prostate Cancer

June 05, 2013

Addition of curcuminoids to treatment with docetaxel was well tolerated and showed promise in improving the response rate to docetaxel “in terms of both PSA decrease and objective response” in a phase II trial in patients with castration-resistant prostate cancer.

ASCO: Sulforaphane in Prostate Cancer Found Worthy of Further Investigation

June 03, 2013

Treatment with 200 µmol per day of sulforaphane for 20 weeks was “feasible, safe,” and inhibited histone deacetylase (HDAC) function in a single-arm study of 20 patients who had non-castrate biochemical (PSA)-recurrence of prostate cancer despite surgery or radiation.